Prometheus Biosciences Inc (RXDX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
CEO:
Mark C. Mckenna
Employees:
70
9410 CARROLL PARK DRIVE, SAN DIEGO, CA 92121
(858) 200-7888

PRA023, a humanized IgG1 monoclonal antibody (mAb) is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule.

Data derived from most recent annual or quarterly report
Market Cap 1.897 Billion Shares Outstanding39.198 Million Avg 30-day Volume 530.411 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue235.3868 Debt to Equity0.0 EBITDA-107.373 Million
Price to Book Value7.1599 Operating Margin-1712.4523 Enterprise Value1.253 Billion
Current Ratio13.564 EPS Growth0 Quick Ratio13.18
1 Yr BETA 1.5155 52-week High/Low 52.3 / 21.12 Profit Margin-1722.5827
Operating Cash Flow Growth-76.9909 Altman Z-Score17.3835 Free Cash Flow to Firm -58.731 Million
View SEC Filings from RXDX instead.

View recent insider trading info

Funds Holding RXDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RXDX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MARSHALL KEITH W CHIEF FINANCIAL OFFICER

  • Officer
86,582 2022-05-20 2

STENHOUSE MARK CHIEF OPERATING OFFICER

  • Officer
86,582 2022-05-20 2

MCKENNA MARK C. CHAIRMAN, PRESIDENT & CEO

  • Officer
  • Director
246,639 2022-05-20 3

HASSAN FRED

  • Director
21,013 2022-05-19 2

PAPA JOSEPH C

  • Director
22,551 2022-05-19 2

SZELA MARY T

  • Director
20,500 2022-05-19 1

SWAIN JUDITH L

  • Director
20,500 2022-05-19 1

ADAMS HELEN C.

  • Director
21,526 2022-05-19 2

LAUR JAMES

  • Director
20,500 2022-05-19 1

HENDRIX MARTIN

  • Director
20,500 2022-05-19 1

CEDARS SINAI INTELLECTUAL PROPERTY CO

  • 10% Owner
4,866,132 2022-04-05 1

ANDREWS TIMOTHY K. GENERAL COUNSEL

  • Officer
54,132 2021-11-14 1

LUO ALLISON CHIEF MEDICAL OFFICER

  • Officer
113,677 2021-11-14 2

POINT72 BIOTECH PRIVATE INVESTMENTS, LLC

DIFFERENTIATED VENTURES INVESTMENTS, LLC

72 INVESTMENT HOLDINGS, LLC

COHEN STEVEN A/SAC CAPITAL MGMT LP

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2021-03-16 0

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
No longer subject to file 2021-03-16 0

RTW INVESTMENTS, LP

WONG RODERICK

  • 10% Owner
No longer subject to file 2021-03-16 0

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

CORMORANT PRIVATE HEALTHCARE FUND III LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2021-03-16 0

BRISTOL JAMES A

  • Director
21,667 2016-08-15 0

CASDIN ALEXANDER W.

  • Director
806,464 2016-05-04 0

LIM JONATHAN E PRESIDENT, CEO & DIRECTOR

  • Officer
  • Director
  • 10% Owner
3,447,000 2016-03-17 0

FREDDO JAMES L

  • Director
3,000 2016-03-17 0

CITY HILL VENTURE PARTNERS I, LLC

  • 10% Owner
3,350,000 2016-03-17 0

CHACKO JACOB CHIEF FINANCIAL OFFICER

  • Officer
42,838 2016-03-17 0

WILD ROBERT SR. VP, RESEARCH AND CSO

  • Officer
1,200 2015-06-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 22:15:03 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 21:45:04 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 21:15:04 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 20:45:04 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 20:15:05 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 19:45:03 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 19:15:05 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 18:45:03 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 18:15:04 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 17:45:04 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 17:15:05 UTC 1.9173 0.4027 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 16:45:04 UTC 1.9218 0.3982 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 16:15:04 UTC 1.9218 0.3982 500000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 15:45:04 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 15:15:05 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 14:45:04 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 14:15:05 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 13:45:04 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 13:15:04 UTC 1.9218 0.3982 250000
PROMETHEUS BIOSCIENCES INC RXDX 2022-08-12 12:45:04 UTC 1.9218 0.3982 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund RXDX -500.0 shares, $-18880.0 2022-03-31 N-PORT

Elevate your investments